The Craniopharyngioma drugs in development market research report provides comprehensive information on the therapeutics under development for Craniopharyngioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Craniopharyngioma. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Craniopharyngioma - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Craniopharyngioma and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Craniopharyngioma by eight companies/universities/institutes. The top development phase for Craniopharyngioma is phase ii with six drugs in that stage. The Craniopharyngioma pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Craniopharyngioma pipeline products market are: F. Hoffmann-La Roche, Shanghai Henlius Biotech and Bristol-Myers Squibb.

The key targets in the Craniopharyngioma pipeline products market include Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1), Dual Specificity Mitogen Activated Protein Kinase Kinase 2 (ERK Activator Kinase 2 or MAPK/ERK Kinase 2 or MAP2K2 or EC 2.7.12.2), and Dual Specificity Mitogen Activated Protein Kinase Kinase 1 (ERK Activator Kinase 1 or MAPK/ERK Kinase 1 or MAP2K1 or EC 2.7.12.2).

The key mechanisms of action in the Craniopharyngioma pipeline product include Serine/Threonine Protein Kinase B Raf (p94 or Proto Oncogene B Raf or v Raf Murine Sarcoma Viral Oncogene Homolog B1 or BRAF or EC 2.7.11.1) Inhibitor with four drugs in Phase II. The Craniopharyngioma pipeline products include seven routes of administration with the top ROA being Oral and three key molecule types in the Craniopharyngioma pipeline products market including Small Molecule, and Monoclonal Antibody.

Craniopharyngioma overview

Craniopharyngioma is a brain tumor that develops near the pituitary gland and the hypothalamus and is slow-growing and non-cancerous. Although these tumors are not cancerous, they may grow to press on nearby parts of the brain, causing symptoms including hormonal changes, vision alteration, headaches, nausea and vomiting, loss of balance, hearing loss, and changes in mood or behavior. The cause of these tumors is not well understood.

For a complete picture of Craniopharyngioma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.